[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse IKBKB

Summary
SymbolIKBKB
Nameinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta
Aliases IKK2; NFKBIKB; IKK-beta; IKKB; IMD15; I-kappa-B kinase 2; I-kappa-B-kinase beta; IKK-B; nuclear factor NF-ka ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus Membrane raft Note=Colocalized with DPP4 in membrane rafts.
Domain PF12179 I-kappa-kinase-beta NEMO binding domain
PF00069 Protein kinase domain
Function

Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. In addition to the NF-kappa-B inhibitors, phosphorylates several other components of the signaling pathway including NEMO/IKBKG, NF-kappa-B subunits RELA and NFKB1, as well as IKK-related kinases TBK1 and IKBKE. IKK-related kinase phosphorylations may prevent the overproduction of inflammatory mediators since they exert a negative regulation on canonical IKKs. Phosphorylates FOXO3, mediating the TNF-dependent inactivation of this pro-apoptotic transcription factor. Also phosphorylates other substrates including NCOA3, BCL10 and IRS1. Within the nucleus, acts as an adapter protein for NFKBIA degradation in UV-induced NF-kappa-B activation.

> Gene Ontology
 
Biological Process GO:0001885 endothelial cell development
GO:0001959 regulation of cytokine-mediated signaling pathway
GO:0002064 epithelial cell development
GO:0002218 activation of innate immune response
GO:0002220 innate immune response activating cell surface receptor signaling pathway
GO:0002221 pattern recognition receptor signaling pathway
GO:0002223 stimulatory C-type lectin receptor signaling pathway
GO:0002224 toll-like receptor signaling pathway
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002753 cytoplasmic pattern recognition receptor signaling pathway
GO:0002756 MyD88-independent toll-like receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0003158 endothelium development
GO:0006470 protein dephosphorylation
GO:0007009 plasma membrane organization
GO:0007043 cell-cell junction assembly
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007252 I-kappaB phosphorylation
GO:0009615 response to virus
GO:0010803 regulation of tumor necrosis factor-mediated signaling pathway
GO:0010921 regulation of phosphatase activity
GO:0010923 negative regulation of phosphatase activity
GO:0016311 dephosphorylation
GO:0018105 peptidyl-serine phosphorylation
GO:0018209 peptidyl-serine modification
GO:0030522 intracellular receptor signaling pathway
GO:0030856 regulation of epithelial cell differentiation
GO:0030865 cortical cytoskeleton organization
GO:0030866 cortical actin cytoskeleton organization
GO:0031098 stress-activated protein kinase signaling cascade
GO:0031349 positive regulation of defense response
GO:0032515 negative regulation of phosphoprotein phosphatase activity
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0034329 cell junction assembly
GO:0034330 cell junction organization
GO:0034612 response to tumor necrosis factor
GO:0035303 regulation of dephosphorylation
GO:0035304 regulation of protein dephosphorylation
GO:0035305 negative regulation of dephosphorylation
GO:0035308 negative regulation of protein dephosphorylation
GO:0035507 regulation of myosin-light-chain-phosphatase activity
GO:0035509 negative regulation of myosin-light-chain-phosphatase activity
GO:0035666 TRIF-dependent toll-like receptor signaling pathway
GO:0035872 nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway
GO:0038093 Fc receptor signaling pathway
GO:0038095 Fc-epsilon receptor signaling pathway
GO:0042501 serine phosphorylation of STAT protein
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043297 apical junction assembly
GO:0043666 regulation of phosphoprotein phosphatase activity
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045216 cell-cell junction organization
GO:0045446 endothelial cell differentiation
GO:0045601 regulation of endothelial cell differentiation
GO:0046425 regulation of JAK-STAT cascade
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050852 T cell receptor signaling pathway
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051092 positive regulation of NF-kappaB transcription factor activity
GO:0051346 negative regulation of hydrolase activity
GO:0051403 stress-activated MAPK cascade
GO:0060759 regulation of response to cytokine stimulus
GO:0061028 establishment of endothelial barrier
GO:0070423 nucleotide-binding oligomerization domain containing signaling pathway
GO:0070498 interleukin-1-mediated signaling pathway
GO:0070555 response to interleukin-1
GO:0070830 bicellular tight junction assembly
GO:0071347 cellular response to interleukin-1
GO:0071356 cellular response to tumor necrosis factor
GO:0072657 protein localization to membrane
GO:0072659 protein localization to plasma membrane
GO:0090002 establishment of protein localization to plasma membrane
GO:0090150 establishment of protein localization to membrane
GO:1901550 regulation of endothelial cell development
GO:1901888 regulation of cell junction assembly
GO:1901889 negative regulation of cell junction assembly
GO:1903140 regulation of establishment of endothelial barrier
GO:1903347 negative regulation of bicellular tight junction assembly
GO:1904892 regulation of STAT cascade
GO:1990778 protein localization to cell periphery
GO:2000810 regulation of bicellular tight junction assembly
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0008384 IkappaB kinase activity
GO:0046982 protein heterodimerization activity
GO:0097110 scaffold protein binding
Cellular Component GO:0008385 IkappaB kinase complex
GO:0009898 cytoplasmic side of plasma membrane
GO:0035631 CD40 receptor complex
GO:0043235 receptor complex
GO:0044445 cytosolic part
GO:0045121 membrane raft
GO:0061695 transferase complex, transferring phosphorus-containing groups
GO:0098552 side of membrane
GO:0098562 cytoplasmic side of membrane
GO:0098589 membrane region
GO:0098802 plasma membrane receptor complex
GO:0098857 membrane microdomain
GO:1902554 serine/threonine protein kinase complex
GO:1902911 protein kinase complex
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04014 Ras signaling pathway
hsa04062 Chemokine signaling pathway
hsa04064 NF-kappa B signaling pathway
hsa04068 FoxO signaling pathway
hsa04150 mTOR signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04210 Apoptosis
hsa04380 Osteoclast differentiation
hsa04620 Toll-like receptor signaling pathway
hsa04621 NOD-like receptor signaling pathway
hsa04622 RIG-I-like receptor signaling pathway
hsa04623 Cytosolic DNA-sensing pathway
hsa04660 T cell receptor signaling pathway
hsa04662 B cell receptor signaling pathway
hsa04668 TNF signaling pathway
hsa04722 Neurotrophin signaling pathway
hsa04910 Insulin signaling pathway
hsa04920 Adipocytokine signaling pathway
Reactome R-HSA-166054: Activated TLR4 signalling
R-HSA-1169091: Activation of NF-kappaB in B cells
R-HSA-1280218: Adaptive Immune System
R-HSA-1236975: Antigen processing-Cross presentation
R-HSA-5621481: C-type lectin receptors (CLRs)
R-HSA-5607764: CLEC7A (Dectin-1) signaling
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1834949: Cytosolic sensors of pathogen-associated DNA
R-HSA-73887: Death Receptor Signalling
R-HSA-1643685: Disease
R-HSA-5602358: Diseases associated with the TLR signaling cascade
R-HSA-5260271: Diseases of Immune System
R-HSA-202424: Downstream TCR signaling
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-1236974: ER-Phagosome pathway
R-HSA-2871837: FCERI mediated NF-kB activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-5603027: IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
R-HSA-937041: IKK complex recruitment mediated by RIP1
R-HSA-937039: IRAK1 recruits IKK complex
R-HSA-975144: IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
R-HSA-5603029: IkBA variant leads to EDA-ID
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-446652: Interleukin-1 signaling
R-HSA-450294: MAP kinase activation in TLR cascade
R-HSA-5684264: MAP3K8 (TPL2)-dependent MAPK1/3 activation
R-HSA-975871: MyD88 cascade initiated on plasma membrane
R-HSA-975155: MyD88 dependent cascade initiated on endosome
R-HSA-166166: MyD88-independent TLR3/TLR4 cascade
R-HSA-166058: MyD88
R-HSA-933543: NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
R-HSA-209560: NF-kB is activated and signals survival
R-HSA-168638: NOD1/2 Signaling Pathway
R-HSA-168643: Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
R-HSA-1810476: RIP-mediated NFkB activation via ZBP1
R-HSA-5357905: Regulation of TNFR1 signaling
R-HSA-162582: Signal Transduction
R-HSA-449147: Signaling by Interleukins
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-445989: TAK1 activates NFkB by phosphorylation and activation of IKKs complex
R-HSA-202403: TCR signaling
R-HSA-75893: TNF signaling
R-HSA-5357956: TNFR1-induced NFkappaB signaling pathway
R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines
R-HSA-933542: TRAF6 mediated NF-kB activation
R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling
R-HSA-168142: Toll Like Receptor 10 (TLR10) Cascade
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168176: Toll Like Receptor 5 (TLR5) Cascade
R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade
R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-1606322: ZBP1(DAI) mediated induction of type I IFNs
R-HSA-193704: p75 NTR receptor-mediated signalling
R-HSA-209543: p75NTR recruits signalling complexes
R-HSA-193639: p75NTR signals via NF-kB
Summary
SymbolIKBKB
Nameinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta
Aliases IKK2; NFKBIKB; IKK-beta; IKKB; IMD15; I-kappa-B kinase 2; I-kappa-B-kinase beta; IKK-B; nuclear factor NF-ka ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IKBKB and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between IKBKB and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26903482MelanomaPromote immunity (T cell function)We hypothesized that forcing T cell-intrinsic NF-κB activation might break this cycle and induce tumor elimination. NF-κB was activated in T cells by inducing the expression of a constitutively active form of the upstream activator IκB kinase β (IKKβ). T cell-restricted constitutively active IKKβ augmented the frequency of functional tumor-specific CD8(+) T cells and improved tumor control.
25336190MelanomaPromote immunityMyeloid IKKβ promotes antitumor immunity by modulating CCL11 and the innate immune response.
Summary
SymbolIKBKB
Nameinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta
Aliases IKK2; NFKBIKB; IKK-beta; IKKB; IMD15; I-kappa-B kinase 2; I-kappa-B-kinase beta; IKK-B; nuclear factor NF-ka ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IKBKB in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -3.57; FDR: 0.00354 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolIKBKB
Nameinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta
Aliases IKK2; NFKBIKB; IKK-beta; IKKB; IMD15; I-kappa-B kinase 2; I-kappa-B-kinase beta; IKK-B; nuclear factor NF-ka ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IKBKB in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2070.335
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1350.937
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2620.829
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3270.231
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4610.839
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1590.957
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1150.758
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2470.879
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0440.981
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4230.765
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9290.653
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1060.167
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IKBKB in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIKBKB
Nameinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta
Aliases IKK2; NFKBIKB; IKK-beta; IKKB; IMD15; I-kappa-B kinase 2; I-kappa-B-kinase beta; IKK-B; nuclear factor NF-ka ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IKBKB. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIKBKB
Nameinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta
Aliases IKK2; NFKBIKB; IKK-beta; IKKB; IMD15; I-kappa-B kinase 2; I-kappa-B-kinase beta; IKK-B; nuclear factor NF-ka ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IKBKB. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IKBKB.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIKBKB
Nameinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta
Aliases IKK2; NFKBIKB; IKK-beta; IKKB; IMD15; I-kappa-B kinase 2; I-kappa-B-kinase beta; IKK-B; nuclear factor NF-ka ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IKBKB. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIKBKB
Nameinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta
Aliases IKK2; NFKBIKB; IKK-beta; IKKB; IMD15; I-kappa-B kinase 2; I-kappa-B-kinase beta; IKK-B; nuclear factor NF-ka ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IKBKB expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIKBKB
Nameinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta
Aliases IKK2; NFKBIKB; IKK-beta; IKKB; IMD15; I-kappa-B kinase 2; I-kappa-B-kinase beta; IKK-B; nuclear factor NF-ka ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IKBKB and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIKBKB
Nameinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta
Aliases IKK2; NFKBIKB; IKK-beta; IKKB; IMD15; I-kappa-B kinase 2; I-kappa-B-kinase beta; IKK-B; nuclear factor NF-ka ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IKBKB collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting IKBKB.
ID Name Drug Type Targets #Targets
DB00244MesalazineSmall MoleculeALOX5, CHUK, IKBKB, MPO, PPARG, PTGS1, PTGS27
DB00795SulfasalazineSmall MoleculeACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC7A11, ......10
DB00945Acetylsalicylic acidSmall MoleculeAKR1C1, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, ......18
DB00995AuranofinSmall MoleculeIKBKB, PRDX52
DB01169Arsenic trioxideSmall MoleculeAKT1, CCND1, CDKN1A, HDAC1, IKBKB, JUN, MAPK1, MAPK3, PML, TXNRD110
DB05183MLN0415Small MoleculeIKBKB1
DB06151AcetylcysteineSmall MoleculeACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, SLC ......10
DB06521ErtiprotafibSmall MoleculeIKBKB, PPARA, PPARG, PTPN14